Cost-Effectiveness of Age-Expanding Strategy of Latent Tuberculosis Infection Treatment in Household Contacts in South Korea
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The strategy of latent tuberculosis infection (LTBI) treatment in household tuberculosis (TB) contacts has been ex panding in South Korea. However, there is little evidence of the cost-effectiveness of LTBI treatment in patients over 35 years of age. This study aimed to evaluate the cost-effectiveness of LTBI treatment among household TB contacts in different age groups in South Korea. Materials and Methods: An age-structured model of TB was developed based on the reports from the Korea Disease Control and Prevention Agency and the National Health Insurance Service. Quality-adjusted life-years (QALY) and the averted number of TB related deaths were estimated along with discounted costs for a measure of incremental cost-effectiveness ratios. Results: The number of cumulative active TB cases would decrease by 1564 and 7450 under the scenario of LTBI treatment for those aged <35 years and <70 years, respectively, relative to the no-treatment scenario. The treatment strategies for patients aged 0 to <35 years, <55 years, <65 years, and <70 years would add 397, 1482, 3782, and 8491 QALYs at a cost of $660, $5930, $4560, and $2530, respectively, per QALY. For the averted TB-related deaths, LTBI treatment targeting those aged 0 to <35 years, <55 years, <65 years, and <70 years would avert 7, 89, 155, and 186 deaths at a cost of $35900, $99200, $111100, and $115700 per deaths, re spectively, in 20 years. Conclusion: The age-specific expansion policy of LTBI treatment not only for those under 35 years of age but also for those under 65 years of age among household contacts was cost-effective in terms of QALYs and averted TB deaths.
Abstract
Purpose: The strategy of latent tuberculosis infection (LTBI) treatment in household tuberculosis (TB) contacts has been ex panding in South Korea. However, there is little evidence of the cost-effectiveness of LTBI treatment in patients over 35 years of age. This study aimed to evaluate the cost-effectiveness of LTBI treatment among household TB contacts in different age groups in South Korea. Materials and Methods: An age-structured model of TB was developed based on the reports from the Korea Disease Control and Prevention Agency and the National Health Insurance Service. Quality-adjusted life-years (QALY) and the averted number of TB related deaths were estimated along with discounted costs for a measure of incremental cost-effectiveness ratios. Results: The number of cumulative active TB cases would decrease by 1564 and 7450 under the scenario of LTBI treatment for those aged <35 years and <70 years, respectively, relative to the no-treatment scenario. The treatment strategies for patients aged 0 to <35 years, <55 years, <65 years, and <70 years would add 397, 1482, 3782, and 8491 QALYs at a cost of $660, $5930, $4560, and $2530, respectively, per QALY. For the averted TB-related deaths, LTBI treatment targeting those aged 0 to <35 years, <55 years, <65 years, and <70 years would avert 7, 89, 155, and 186 deaths at a cost of $35900, $99200, $111100, and $115700 per deaths, re spectively, in 20 years. Conclusion: The age-specific expansion policy of LTBI treatment not only for those under 35 years of age but also for those under 65 years of age among household contacts was cost-effective in terms of QALYs and averted TB deaths.
참고문헌 (33)
- Global tuberculosis report 2022, "World Health Organization", World Health Organization, ~ (2022)
- "Sustainable development goals"[URL]
- "The end TB strategy"[URL]
- World Health Organization, "WHO consolidated guidelines on tuberculosis. Module 1: prevention. Tuberculosis preventive treatment", World Health Organization, ~ (2020)
- Getahun H, "Latent Mycobacterium tuberculosis infection", N Engl J Med, 372, pp.2127~2135 (2015)
- Annual TB report 2021, "Korea Disease Control and Prevention Agency", Korea Disease Control and Prevention Agency, ~ (2022)
- Go U, "Tuberculosis prevention and care in Korea : evolution of policy and practice", J Clin Tuberc Other Mycobact Dis, 11, pp.28~36 (2018)
- Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "Korean guidelines for tuberculosis" (2017), Korea Centers for Disease Control and Prevention
- "Medical pricing information"[URL]
- "Health Insurance Statistical Yearbook"[URL]
- "Population trend survey number of births, total fertility rate, natural increase, etc"[URL]
- Sloot R, "Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam", Am J Respir Crit Care Med, 190, pp.1044~1052 (2014)
- Gibson PG, "Evidence-based respiratory medicine" (2008), John Wiley & Sons
- Annual report on the notified tuberculosis patients in Korea, "Korea Centers for Disease Control and Prevention", Korea Centers for Disease Control and Prevention, ~ (2019)
- "Tuberculosis data"[URL]
- Park Y, "Diagnosis, treatment and outcomes of latent tuberculosis in the household contact investigation programme", Public Health Wkly Rep, 13, pp.1231~1246 (2019)
- Choi JC, "Diagnosis, treatment, and outcomes of latent tuberculosis in the household contact investigation programme", Korea Diseases Control and Prevention Agency, ~ (2021)
- Abu-Raddad LJ, "Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics", Proc Natl Acad Sci U S A, 106, pp.13980~13985 (2009)
- Mossong J, "Social contacts and mixing patterns relevant to the spread of infectious diseases", PLoS Med, 5, pp.e74~ (2008)
- Menzies NA, "Impact of effective global tuberculosis control on health and economic outcomes in the United States", Am J Respir Crit Care Med, 202, pp.1567~1575 (2020)
- Guo N, "Health state utilities in latent and active tuberculosis", Value Health, 11, pp.1154~1161 (2008)
- de Perio MA, "Costeffectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers", Arch Intern Med, 169, pp.179~187 (2009)
- National Institute for Health and Care Excellence, "Guide to the methods of technology appraisal 2013", National Institute for Health and Care Excellence, ~ (2013)
- Shiroiwa T, "International survey on willingness-to-pay(WTP)for one additional QALY gained : what is the threshold of cost effectiveness?", Health Econ, 19, pp.422~437 (2010)
- Alsdurf H, "The cascade of care in diagnosis and treatment of latent tuberculosis infection : a systematic review and meta-analysis", Lancet Infect Dis, 16, pp.1269~1278 (2016)
- Bastos ML, "The latent tuberculosis cascade-of-care among people living with HIV : a systematic review and meta-analysis", PLoS Med, 18, pp.e1003703~ (2021)
- Cadena AM, "Heterogeneity in tuberculosis", Nat Rev Immunol, 17, pp.691~702 (2017)
- Drain PK, "Incipient and subclinical tuberculosis : a clinical review of early stages and progression of infection", Clin Microbiol Rev, 31, pp.e00021-18~ (2018)
- Barnes DS, "The making of a social disease: tuberculosis in nineteenth-century France" (1992), University of California
- Blower SM, "The intrinsic transmission dynamics of tuberculosis epidemics", Nat Med, 1, pp.815~821 (1995)
- Blythe SP, "Toward a unified theory of sexual mixing and pair formation", Math Biosci, 107, pp.379~405 (1991)
- Dye C, "Global burden of tuberculosis : estimated incidence, prevalence, and mortality by country", JAMA, 282, pp.677~686 (1999)
- Aparicio JP, "Markers of disease evolution : the case of tuberculosis", J Theor Biol, 215, pp.227~237 (2002)